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In 2002, revised guidelines for preventing perinatal
group B streptococcal disease were published. In 2002, all
Minnesota providers surveyed reported using a prevention
policy. Most screen vaginal and rectal specimens at 34–37
weeks of gestation. The use of screening-based methods
has increased dramatically since 1998.
G
roup B streptococci (GBS) emerged as the leading
cause of invasive bacterial infections in newborns in
the United States in the 1970s. Although the incidence of
GBS disease has declined substantially, it remains the
leading cause of serious infection in newborns (1).
Perinatal GBS transmission can be reduced dramatically
by diagnosing maternal GBS colonization and administer-
ing intrapartum antimicrobial prophylaxis (IAP) during
labor and delivery (2).
In 1996, the Centers for Disease Control and
Prevention (CDC) published consensus guidelines recom-
mending 2 methods of perinatal GBS disease prevention.
The screening-based approach recommends obtaining
vaginal and rectal cultures at 35–37 weeks of gestation.
Women with GBS-positive cultures are offered IAP during
labor. The risk-based approach recommends administering
IAP to women with GBS risk factors when they go into
labor (3). These guidelines are believed to have increased
use of GBS disease prevention approaches by prenatal care
providers, which has led to a decrease in the incidence of
GBS disease (1,4). A2002 study further indicated that rou-
tine screening for GBS would prevent ≈50% more new-
born GBS infections than would a risk-based approach (5).
This study, along with other data, led CDC to publish
revised guidelines in August 2002 recommending univer-
sal prenatal screening (6).
As part of the Minnesota Department of Health
Emerging Infections Program, prenatal care providers in
Minnesota were surveyed in April 1998 to determine
strategies to prevent perinatal GBS disease (7). In
November 2002, a similar survey was undertaken to deter-
mine the extent to which Minnesota providers have adopt-
ed the revised 2002 CDC guidelines.
The Study
In 2002, all licensed obstetricians and certified nurse
midwives in Minnesota were surveyed. All family practi-
tioners who listed obstetrics as a secondary specialty and a
20% random sample of the remaining licensed family
practitioners were surveyed. In 1998, surveys were mailed
to a random sample of 50% of obstetricians and 25% of
family practitioners who indicated on their licensure appli-
cation that they provided prenatal care. All midwives were
surveyed. Statistical analysis was performed with EpiInfo
software (Centers for Disease Control and Prevention,
Atlanta, GA, USA).
Three mailings were sent during each study period. A
total of 463 surveys (60% of those mailed) were complet-
ed in 2002, and 515 surveys (80% of those mailed) were
completed in 1998. Providers who did not provide prena-
tal care were excluded from further analysis. The final
sample included 97 midwives, 189 obstetricians, and 64
family practitioners in 2002 and 102 midwives, 128 obste-
tricians, and 201 family practitioners in 1998. No signifi-
cant differences were found in provider characteristics
(location, practice type, and number of deliveries per-
formed) from 1998 to 2002.
In 2002, all providers surveyed indicated they had a
policy to prevent perinatal GBS disease. Of these, 318
(91% [96% of obstetricians, 92% of midwives, and 73% of
family practitioners]) indicated their policy was based
upon at least 1 previously published guideline. Family
practitioners (p<0.05) and midwives (p<0.05) were signif-
icantly more likely to follow published guidelines during
2002 than during 1998.
In 1998, the risk-based approach was the most common
method of preventing GBS disease (Table 1). In 2002, the
screening-based approach was the most common method.
In 2002, providers were significantly more likely to have
adopted a screening-based approach to prevention than
they were in 1998 (p<0.001). In 2002, when risk-based
providers were questioned, 14 (52%) of 27 midwives, 5
(50%) of 10 family practitioners, and 6 (32%) of 19 obste-
tricians indicated they planned to implement the new
guidelines.
In 2002, among those who reported a screening-based
approach, 262 (89%) of 293 providers routinely collected
specimens from both vaginal and rectal sites. Midwives
(97%) were more likely than obstetricians (90%) and fam-
ily practitioners (77%) to collect specimens from both
sites. In 2002, midwives (p<0.001) were significantly
more likely to use both vaginal and rectal sites to screen
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the proportion of obstetricians or family practitioners who
screened vaginal and rectal specimens from 1998 to 2002
(Table 2).
Among providers who used a screening-based
approach to prevent perinatal GBS infection in 2002, most
(88%) obtained cultures at 35–37 weeks of gestation. No
change was seen in the proportion of providers who
screened at 35–37 weeks of gestation when responses from
the 1998 and 2002 surveys were compared (Table 2).
In 2002, when providers were asked if their laboratories
used a selective broth to isolate GBS, 171 (58%) of 293
indicated that they did. Obstetricians were significantly
more likely than midwives and family practitioners to
report selective broth use in their laboratories.
Obstetricians (p<0.001) were significantly more likely to
report that their laboratory used selective broth in 2002
than in 1998 (Table 2). Little change was seen among mid-
wives and family practitioners regarding their knowledge
of selective broth use from 1998 to 2002.
In 2002, a total of 225 (77%) of 292 providers reported
using penicillin most often for IAP. Midwives and obstetri-
cians were more likely than family practitioners to report
using penicillin. Midwives (p<0.01) were significantly
more likely to use penicillin in 2002 than they were in
1998. Little change was seen in the proportion of family
practitioners and obstetricians who used penicillin in 1998
versus 2002 (Table 2).
Conclusions
The results of this survey suggest that all Minnesota
providers have adopted a policy on preventing perinatal
GBS disease, and most follow established, published
guidelines. In 1998, a risk-based approach to GBS disease
prevention was the most common strategy identified by
providers. In 2002, screening all pregnant women for GBS
was the predominant strategy.
The effectiveness of the screening-based approach
depends partly on the sensitivity and specificity of the
specimens collected. A previous study by Philipson et al.
indicated that swabbing both vaginal and rectal sites sig-
nificantly increased the sensitivity of isolating GBS com-
pared with swabbing the vagina only (8). In our study, 89%
of Minnesota providers indicated they routinely collected
specimens for GBS screening from both vaginal and rectal
sites. Because vaginal and rectal swabs are likely to yield
diverse bacteria, selective broth is recommended to limit
growth of other organisms, thus increasing the chance of
isolating GBS (9). In a study by Silver and Struminski,
≈32% of women had false-negative culture results when
direct agar plating was used instead of selective broth to
isolate GBS (10). In our study, most obstetricians (72%)
indicated that their laboratories used selective broth; how-
ever, less than half of midwives and family practitioners
reported using selective broth. Many providers (41%) did
not know whether their laboratories used selective broth. A
recent survey found that 89% of laboratories that process
GBS specimens use selective enrichment broth media for
GBS isolation (11). Preliminary data from a 2004 survey
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tories use a selective enrichment broth media to isolate
GBS (Minnesota Department of Health, unpub. data).
Collecting cultures late in the gestational period is more
likely to detect women who are colonized when they deliv-
er, compared to screening at an earlier stage of a woman’s
pregnancy. In 2002, most (88%) providers who reported a
screening-based approach to perinatal GBS disease pre-
vention obtained cultures at 35–37 weeks of gestation.
Research in the 1980s showed that administering
antimicrobial prophylaxis to women who are colonized
with GBS was effective in preventing disease in newborns.
Because of its narrow spectrum, penicillin remains the pre-
ferred drug of choice. Ampicillin, a broader-spectrum
agent, is considered an acceptable alternative. In our study,
>80% of obstetricians and midwives reported using peni-
cillin as their first choice for IAP. Although family practi-
tioners were significantly more likely to use penicillin in
2002 than in 1998, only 51% of family practitioners listed
penicillin as their first choice.
Several factors should be considered when interpreting
the results of this study. First, the survey was conducted
only among Minnesota providers, so the results may not be
generalized to other states. Second, the overall response
rate was 80% in 1998 and 60% in 2002. This decrease is
most likely explained by a sampling change in which a
greater proportion of family practitioners with a history of
providing prenatal care were sampled in 1998 than in
2002. We suspect that most family practitioners who failed
to complete the survey in 2002 did so because they did not
provide prenatal care. When characteristics of responders
in 1998 and 2002 were compared, no significant differ-
ences were noted regarding location of practice, practice
type, size of practice, and median number of deliveries
performed. Finally, surveys are measures of reported prac-
tices and may not reflect actual services provided.
Prenatal care providers, especially family practitioners,
should continue to discuss and establish policies regarding
perinatal GBS disease prevention. Providers should be
educated about optimal specimen sites and timing of
screening. Education on using selective broth medium to
isolate GBS should be provided to clinicians and laborato-
ries. In addition, clinicians should be familiar with the
appropriate antimicrobial agents used for IAP and ensure
rapid drug administration when it is indicated.
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